Paper Details

  1. Home
  2. Paper Details

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.

Author: BernhardAna, BreinholtVibeke Miller, FaltingerFrank, HerselUlrich, Kjelgaard-HansenMads, MygindPer Holse, RasmussenCaroline E, ZettlerJoachim

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

TransCon CNP is a long-acting formulation of C-type natriuretic peptide (CNP) being developed for achondroplasia-related comorbidities. Preclinical studies show that TransCon CNP, compared to short-acting CNP, provides sustained CNP levels, stimulates bone growth, and is well tolerated with no cardiovascular side effects.
Paper Details　
Original Abstract of the Article :
TransCon CNP is a C-type natriuretic peptide (CNP-38) conjugated via a cleavable linker to a polyethylene glycol carrier molecule, designed to provide sustained systemic CNP levels upon weekly subcutaneous administration. TransCon CNP is in clinical development for the treatment of comorbidities ass...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1124/jpet.119.258251

データ提供：米国国立医学図書館（NLM）

TransCon CNP: A Sustained-Release C-Type Natriuretic Peptide Prodrug for Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias

The field of [pharmacology] is constantly seeking to develop new and innovative drug delivery systems. This study focuses on TransCon CNP, a sustained-release prodrug of C-type natriuretic peptide (CNP-38). The authors describe the design and development of TransCon CNP, emphasizing its potential as a safe and efficacious treatment for comorbidities associated with fibroblast growth factor receptor 3 (FGFR3)-related skeletal dysplasias, such as achondroplasia. Preclinical studies in mice and monkeys demonstrated that sustained exposure to CNP via TransCon CNP was more effective in stimulating bone growth than intermittent CNP exposure. The authors also highlight the favorable safety profile of TransCon CNP, emphasizing its lack of adverse cardiovascular effects at therapeutic exposure levels. The findings suggest that TransCon CNP could offer a promising treatment option for FGFR3-related skeletal dysplasias.

TransCon CNP: A Potential Breakthrough for FGFR3-Related Skeletal Dysplasias

This study presents promising preclinical data supporting the potential of TransCon CNP as a safe and effective treatment for FGFR3-related skeletal dysplasias. The authors' findings highlight the significant advantages of sustained CNP release and the potential for improved bone growth and quality of life for individuals with these conditions.

The Promise of Innovative Drug Delivery Systems

As a seasoned traveler through the vast desert of medical knowledge, I am always excited by advancements in drug delivery systems. This study highlights the potential of TransCon Technology to improve drug efficacy and safety. The authors' findings offer hope for individuals with FGFR3-related skeletal dysplasias, suggesting a new era of therapeutic possibilities.

Dr.Camel's Conclusion

This study presents promising preclinical data supporting the potential of TransCon CNP as a safe and effective treatment for FGFR3-related skeletal dysplasias. The authors' findings highlight the advantages of sustained CNP release and the potential for improved bone growth and quality of life for individuals with these conditions.

Date :
  1. Date Completed 2019-12-30
  2. Date Revised 2019-12-30
Further Info :

Pubmed ID

31235532

DOI: Digital Object Identifier

10.1124/jpet.119.258251

Related Literature

Article Analysis
・Effects of vosoritide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.